GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor

Molecular Endocrinology

Volumn 28, Issue 1, 2014, Pages 80-98

  Cho Clark, Madelaine ^a   Larco, Darwin O ^a   Semsarzadeh, Nina N ^c   Vasta, Florencia ^a   Mani, Shaila K ^b   John Wu, T ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Baylor College of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 101; GONADORELIN; GONADORELIN (1-5); ITURELIX; SMALL INTERFERING RNA; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CELL MIGRATION; DOWN REGULATION; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; EXTRACELLULAR CALCIUM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

CALCIUM SIGNALING; CELL LINE, TUMOR; CELL MOVEMENT; ENDOMETRIAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; OLIGOPEPTIDES; ONCOGENE PROTEINS; PEPTIDE FRAGMENTS; PHENYLALANINE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRROLIDONECARBOXYLIC ACID; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; RECEPTORS, LHRH; THIOPHENES; TRANSCRIPTIONAL ACTIVATION; TYRPHOSTINS;

EID: 84891502388     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1203     Document Type: Article

References (83)

1. Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the porcine LH-and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971;43: 1334-1339.
2. Burgus R, Butcher M, Amoss M, et al. Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF) (LH-hypothalamus-LRF-gas chromatography-mass spectrometrydecapeptide-Edman degradation). Proc Natl Acad Sci USA. 1972; 69:278-282.
3. Tsai PS. Gonadotropin-releasing hormone in invertebrates: structure, function, and evolution. Gen Comp Endocrinol. 2006;148(1): 48-53.
4. Tsai PS, Maldonado TA, Lunden JB. Localization of gonadotropinreleasing hormone in the central nervous system and a peripheral chemosensory organ of Aplysia californica. Gen Comp Endocrinol. 2003;130(1):20-28.
5. Srkalovic G, Wittliff JL, Schally AV. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res. 1990;50(6):1841-1846.
6. Kottler ML, Starzec A, Carre MC, Lagarde JP, Martin A, Counis R. The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Intl J Cancer. 1997;71(4):595-599.
7. Wolfahrt S, Kleine B, Rossmanith WG. Detection of gonadotrophin releasing hormone and its receptor mRNA in human placental trophoblasts using in-situ reverse transcription-polymerase chain reaction. Mol Human Reprod. 1998;4(10):999-1006.
8. Gründker C, Günthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol. 2002;146(1):1-14.
9. Emons G, Ortmann O, Schulz KD, Schally AV. Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab. 1997;8(9):355-362.
10. Emons G, Ortmann O, Becker M, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res. 1993;53(22):5439-5446.
11. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metabol. 1992;75(1):207-212.
12. Gallagher CJ, Oliver RT, Oram DH, et al. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol. 1991;98(10):1037-1041.
13. Mullen P, Scott WN, Miller WR. Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer. 1991;63(6):930-932.
14. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM. Growth of human breast cancer cells inhibited by a luteinizing hormonereleasing hormone agonist. Nature. 1985;313(5999):231-233.
15. Moretti RM, Monagnani Marelli M, van Groeninghen JC, Motta M, Limonta P. Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. Endocr-Related Cancer. 2003;10(2):161-167.
16. Imai A, Horibe S, Takagi H, Fuseya T, Tamaya T. Signal transduction of GnRH receptor in the reproductive tract tumor. Endocrine J. 1996;43(3):249-260.
17. So WK, Cheng JC, Poon SL, Leung PC. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J. 2008;275(22):5496-5511.
18. Grundker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003;1:65.
19. Baldwin EL, Wegorzewska IN, Flora M, Wu TJ. Regulation of type II luteinizing hormone-releasing hormone (LHRH-II) gene expression by the processed peptide of LHRH-I, LHRH-(1-5) in endometrial cells. Exp Biol Med (Maywood). 2007;232(1):146-155.
20. Walters K, Chin YP, Wu TJ. A processed metabolite of luteinizing hormone-releasing hormone has proliferative effects in endometrial cells. Am J Obstet Gynecol. 2007;196(1):33 e31-e35.
21. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD, Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metabol. 1993;77(6): 1458-1464.
22. Molineaux CJ, Lasdun A, Michaud C, Orlowski M. Endopeptidase-24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo. J Neurochem. 1988;51(2):624-633.
23. Wu TJ, Pierotti AR, Jakubowski M, et al. Endopeptidase EC 3.4.24.15 presence in the rat median eminence and hypophysial portal blood and its modulation of the luteinizing hormone surge. J Neuroendocrinol. 1997;9(11):813-822.
24. Wu TJ, Mani SK, Glucksman MJ, Roberts JL. Stimulation of luteinizing hormone-releasing hormone (LHRH) gene expression in GT1-7 cells by its metabolite, LHRH-(1-5). Endocrinol. 2005; 146(1):280-286.
25. Wu TJ, Glucksman MJ, Roberts JL, Mani SK. Facilitation of lordosis in rats by a metabolite of luteinizing hormone releasing hormone. Endocrinology. 2006;147(5):2544-2549.
26. Songyang Z, Shoelson SE, Chaudhuri M, et al. SH2 domains recognize specific phosphopeptide sequences. Cell. 1993;72(5):767-778.
27. Emlet DR, Moscatello DK, Ludlow LB, Wong AJ. Subsets of epidermal growth factor receptors during activation and endocytosis. J Biol Chem. 1997;272(7):4079-4086.
28. Sorkin A, Waters C, Overholser KA, Carpenter G. Multiple autophosphorylation site mutations of the epidermal growth factor receptor. Analysis of kinase activity and endocytosis. J Biol Chem. 1991;266(13):8355-8362.
29. Rotin D, Honegger AM, Margolis BL, Ullrich A, Schlessinger J. Presence of SH2 domains of phospholipase C γ 1 enhances substrate phosphorylation by increasing the affinity toward the epidermal growth factor receptor. J Biol Chem. 1992;267(14):9678-9683.
30. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K. [Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors]. Nihon Sanka Fujinka Gakkai Zasshi. 1985;37(7):1103-1111.
31. Mukai H, Munekata E, Higashijima T. G protein antagonists. A novel hydrophobic peptide competes with receptor for G protein binding. J Biol Chem. 1992;267(23):16237-16243.
32. Eguchi S, Numaguchi K, Iwasaki H, et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 1998;273(15):8890-8896.
33. Yang CM, Lee IT, Lin CC, Wang CH, Cherng WJ, Hsiao LD. c-Src-dependent MAPKs/AP-1 activation is involved in TNF-α-induced matrix metalloproteinase-9 expression in rat heart-derived H9c2 cells. Biochem Pharmacol. 2013;85(8):1115-1123.
34. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol. 2008;22(8):1781-1796.
35. Panigone S, Hsieh M, Fu M, Persani L, Conti M. Luteinizing hormone signaling in preovulatory follicles involves early activation of the epidermal growth factor receptor pathway. Mol Endocrinol. 2008;22(4):924-936.
36. Pszczolkowski MA, Peterson A, Srinivasan A, Ramaswamy SB. Pharmacological analysis of ovarial patency in Heliothis virescens. J Insect Physiol. 2005;51(4):445-453.
37. Hong IS, Klausen C, Cheung AP, Leung PC. Gonadotropin-releasing hormone-I or-II interacts with IGF-I/Akt but not connexin 43 in human granulosa cell apoptosis. J Clin Endocrinol Metab. 2012; 97(2):525-534.
38. Larco DO, Cho-Clark M, Mani SK, Wu TJ. The metabolite GnRH-(1-5) inhibits the migration of immortalized GnRH neurons. Endocrinology. 2013;154(2):783-795.
39. Olson KR, Eglen RM. β galactosidase complementation: a cellbased luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007;5(1):137-144.
40. van Der Lee MM, Bras M, van Koppen CJ, Zaman GJ. β-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1. J Biomol Screen. 2008;13(10): 986-998.
41. Kober P, Bujko M, Oledzki J, Tysarowski A, Siedlecki JA. Methyl-CpG binding column-based identification of nine genes hypermethylated in colorectal cancer. Mol Carcinog. 2011;50(11):846-856.
42. Alexander B, Browse DJ, Reading SJ, Benjamin IS. A simple and accurate mathematical method for calculation of the EC50. J Pharmacol Toxicol Methods. 1999;41(2-3):55-58.
43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) method. Methods. 2001;25(4):402-408.
44. Mani SK, Blaustein JD, Allen JM, Law SW, O'Malley BW, Clark JH. Inhibition of rat sexual behavior by antisense oligonucleotides to the progesterone receptor. Endocrinology. 1994;135(4):1409-1414.
45. Dougherty GW, Jose C, Gimona M, Cutler ML. The Rsu-1-PINCH1-ILK complex is regulated by Ras activation in tumor cells. Eur J Cell Biol. 2008;87(8-9):721-734.
46. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene. 2010; 29(35):4947-4958.
47. Zhang Y, Chen K, Guo L, Wu C. Characterization of PINCH-2, a new focal adhesion protein that regulates the PINCH-1-ILK interaction, cell spreading, and migration. J Biol Chem. 2002;277(41): 38328-38338.
48. Gründker C, Völker P, Schulz KD, Emons G. Luteinizing hormonereleasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol. 2000;78(2):194-202.
49. Grundker C, Volker P, Emons G. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein α(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology. 2001;142(6):2369-2380.
50. Huang YT, Hwang JJ, Lee LT, et al. Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells. Intl J Cancer. 2002;99(4):505-513.
51. Ko YH, Ha YR, Kim JW, et al. Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145. J Int Med Res. 2011;39(3):729-739.
52. Katsila T, Balafas E, Liapakis G, et al. Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer. J Pharmacol Exp Therapeut. 2011;336(3):613-623.
53. Günthert AR, Gründker C, Olota A, Läsche J, Eicke N, Emons G. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factorinduced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. Eur J Endocrinol. 2005;153(4): 613-625.
54. Eicke N, Gunthert AR, Emons G, Grundker C. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells. Intl J Oncol. 2006;29(5):1223-1229.
55. WuHM, Cheng JC, Wang HS, Huang HY, MacCalman CD, Leung PC. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45α. Cancer Res. 2009;69(10):4202-4208.
56. Morgan K, Stavrou E, Leighton SP, Miller N, Sellar R, Millar RP. Elevated GnRH receptor expression plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized human prostate cells. Prostate. 2011;71(9):915-928.
57. Thompson MA, Adelson MD, Kaufman LM. Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab. 1991;72(5):1036-1041.
58. Carbajal L, Biswas A, Niswander LM, Prizant H, Hammes SR. GPCR/EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary. Mol Endocrinol. 2011;25(6):1055-1065.
59. Dong J, Opresko LK, Dempsey PJ, Lauffenburger DA, Coffey RJ, Wiley HS. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci USA. 1999;96(11):6235-6240.
60. Ljungqvist A, Feng DM, Hook W, Shen ZX, Bowers C, Folkers K. Antide and related antagonists of luteinizing hormone release with long action and oral activity. Proc Natl Acad Sci USA. 1988;85(21): 8236-8240.
61. Rivier J, Theobald P, Porter J, et al. Gonadotropin releasing hormone antagonists: novel structures incorporating N omega-cyano modified guanidine moieties. Biochem Biophys Res Commun. 1991;176(1):406-412.
62. Shrimpton CN, Smith AI, Lew RA. Soluble metalloendopeptidases and neuroendocrine signaling. Endocrine Rev. 2002;23(5):647-664.
63. Imai A, Iida K, Furui T, Tamaya T. Evidence for hormone-responsive cleavage of gonadotropin-releasing hormone by the plasma membrane of ovarian cancer cells. Intl J Oncol. 2002;20(5):987-992.
64. Sorianello EM, Fernandez MO, Catalano PN, et al. Differential gonadotropin releasing hormone (GnRH) expression, autoregulation and effects in two models of rat luteinized ovarian cells. Life Sci. 2005;77(17):2141-2155.
65. Swanson TA, Kim SI, Myers M, et al. The role of neuropeptide processing enzymes in endocrine (prostate) cancer: EC 3.4.24.15 (EP24.15). Protein Pept Lett. 2004;11(5):471-478.
66. Poon SL, Hammond GT, Leung PC. Epidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasion. Mol Endocrinol. 2009;23(10):1646-1656.
67. Ling Poon S, Lau MT, Hammond GL, Leung PC. Gonadotropinreleasing hormone-II increases membrane type I metalloproteinase production via β-catenin signaling in ovarian cancer cells. Endocrinology. 2011;152(3):764-772.
68. Poon SL, Klausen C, Hammond GL, Leung PC. 37-kDa laminin receptor precursor mediates GnRH-II-induced MMP-2 expression and invasiveness in ovarian cancer cells. Mol Endocrinol. 2011; 25(2):327-338.
69. Wu HM, Wang HS, Huang HY, et al. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogenactivated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2. BMC Cancer. 2013;13(1):300.
70. Cheung LW, Leung PC, Wong AS. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res. 2006;66(22):10902-10910.
71. Navratil AM, Knoll JG, Whitesell JD, Tobet SA, Clay CM. Neuroendocrine plasticity in the anterior pituitary: gonadotropin-releasing hormone-mediated movement in vitro and in vivo. Endocrinology. 2007;148(4):1736-1744.
72. Godoy J, Nishimura M, Webster NJ. Gonadotropin-releasing hormone induces miR-132 and miR-212 to regulate cellular morphology and migration in immortalized LβT2 pituitary gonadotrope cells. Mol Endocrinol. 2011;25(5):810-820.
73. Bates B, Zhang L, Nawoschik S, et al. Characterization of Gpr101 expression and G-protein coupling selectivity. Brain Res. 2006; 1087(1):1-14.
74. Lee DK, Nguyen T, Lynch KR, et al. Discovery and mapping of ten novelGprotein-coupled receptor genes. Gene. 2001;275(1):83-91.
75. Vassilatis DK, Hohmann JG, Zeng H, et al. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci USA. 2003;100(8):4903-4908.
76. Keely SJ, Calandrella SO, Barrett KE. Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) cells is mediated by intracellular ca(2+), PYK-2, and p60(src). J Biol Chem. 2000;275(17):12619-12625.
77. Andreev J, Galisteo ML, Kranenburg O, et al. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogenactivated protein (MAP) kinase signaling cascade. J Biol Chem. 2001;276(23):20130-20135.
78. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ, Lefkowitz RJ. Role of c-Src tyrosine kinase in G protein-coupled receptor-and Gβγ subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem. 1996;271(32):19443-19450.
79. Liebmann C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol. 2011;331(2): 222-231.
80. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(suppl 4):S9-S15.
81. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8-13.
82. Shah BH, Farshori MP, Catt KJ. Neuropeptide-induced transactivation of a neuronal epidermal growth factor receptor is mediated by metalloprotease-dependent formation of heparin-binding epidermal growth factor. J Biol Chem. 2004;279(1):414-420.
83. Roelle S, Grosse R, Aigner A, Krell HW, Czubayko F, Gudermann T. Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem. 2003;278(47):47307-47318.